The first large randomised trial performed to evaluate therapy for aspergillosis demonstrated improved outcomes and survival in patients randomised to receive voriconazole as primary therapy.
评估曲霉菌病治疗的第一个大型随机试验证实，随机接受伏立康唑作为主要治疗的患者临床结局和生存更佳。
The first large randomised trial performed to evaluate therapy for aspergillosis demonstrated improved outcomes and survival in patients randomised to receive voriconazole as primary therapy.
评估曲霉菌病治疗的第一个大型随机试验证实，随机接受伏立康唑作为主要治疗的患者临床结局和生存更佳。
应用推荐